Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study
暂无分享,去创建一个
Y. Ohashi | H. Akaza | S. Naito | T. Tsukamoto | T. Nishiyama | T. Ueda | S. Ozono | H. Maeda | Mototsugu Ito | Rio Akazawa | H. Kusuoka
[1] Joel T Dudley,et al. Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] T. Choueiri,et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. , 2016, JAMA oncology.
[3] Kazuto Ito,et al. Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist , 2015, Basic and Clinical Andrology.
[4] D. Siemens,et al. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[5] X. Maldonado,et al. Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies , 2015, Clinical and Translational Oncology.
[6] F. Saad,et al. The impact of androgen‐deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non‐metastatic prostate cancer: a population‐based study , 2014, BJU international.
[7] B. Tombal,et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. , 2014, European urology.
[8] S. Horie,et al. Serum level of follicle-stimulating hormone is associated with extraprostatic extension of prostate cancer , 2013, Prostate international.
[9] E. Crawford,et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists , 2012, Prostate Cancer and Prostatic Diseases.
[10] T. Tammela,et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. , 2012, Urology.
[11] Y. Ohashi,et al. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. , 2012, Japanese journal of clinical oncology.
[12] B. Persson,et al. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer , 2011, Therapeutic advances in urology.
[13] E. Crawford,et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. , 2010, European urology.
[14] F. Schröder,et al. The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.
[15] H. Akaza,et al. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer]. , 2001, Hinyokika kiyo. Acta urologica Japonica.
[16] Z-Q Tao,et al. Epidemiology of prostate cancer: current status. , 2015, European review for medical and pharmacological sciences.
[17] Tao Zq,et al. Epidemiology of prostate cancer: current status. , 2015 .
[18] E. Crawford,et al. Adverse events associated with hormonal therapy for prostate cancer. , 2005, Reviews in urology.
[19] Kazuto Ito,et al. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. , 2002, Hinyokika kiyo. Acta urologica Japonica.